MetaVia is a clinical-stage biotech focused on cardiometabolic diseases, with two licensed drug candidates. MetaVia licenses both compounds globally (ex-Korea) from Dong-A ST, a South Korean pharma company, which also handles manufacturing. The company has eight employees and no commercial revenue, funding operations through equity raises. MetaVia's lead asset, vanoglipel (DA-1241), is an oral, once-daily GPR119 agonist targeting MASH, a progressive liver disease, with secondary potential in Type 2 Diabetes. Vanoglipel completed Phase 2a in late 2024 with positive results, and MetaVia is planning a Phase 2b trial. The second asset, DA-1726, is a once-weekly injectable dual GLP-1/glucagon receptor agonist for obesity. The dual mechanism aims to suppress appetite via GLP-1 while increasing energy expenditure via the glucagon receptor — a combination not present in approved GLP-1 drugs. DA-1726 is in Phase 1, with Phase 1 titration studies planned for mid-2026. MetaVia also holds four legacy programs in COVID-19, diabetic neuropathy, neurodegeneration, and dyslipidemia, none of which are being actively advanced; these are held for out-licensing or divestiture. MetaVia's path to value is to advance both lead assets through trials, then either partner with or out-license to a larger pharma company in exchange for upfront payments, milestones, and royalties.